Neutropenic fever sepsis syndromes are common among patients with cancer who are receiving intensive cytotoxic systemic therapy. Recognition of the syndromes and timely initial antibacterial therapy is critical for survival and treatment success. Outcomes are linked to myeloid reconstitution and recovery from neutropenia, control of active comorbidities, and appropriate treatment of the infections that underlie the sepsis syndrome. Hematologists and oncologists must be clear about the prognosis and treatment goals to work effectively with critical care physicians toward the best outcomes for patients with cancer who develop neutropenic sepsis syndromes.
Keywords: Febrile mucositis; Febrile neutropenia; First neutropenic fever; Myelosuppression; Neutropenia; Neutropenic sepsis syndromes; Persistent neutropenic fever; Recrudescent neutropenic fever.
Copyright © 2013 Elsevier Inc. All rights reserved.